Publications by authors named "Cixin S He"
Article Synopsis
- - The CLEAR trial demonstrated that lenvatinib plus pembrolizumab was more effective than sunitinib in treating advanced renal cell carcinoma, particularly in the East Asian patient subset, which showed a median progression-free survival of 22.1 months versus 11.1 months with sunitinib.
- - In the East Asian group (213 patients), the objective response rate was also higher for the lenvatinib plus pembrolizumab combo at 65.3% compared to 49.2% for sunitinib.
- - Treatment-related side effects were common, with hand-foot syndrome appearing in 66.7% of those on lenvatinib plus pembrolizumab, indicating
Background: Results from the phase 3 CLEAR study showed that lenvatinib plus pembrolizumab improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma. We aimed to assess the health-related quality-of-life (HRQOL) outcomes from the CLEAR study.
Methods: This open-label, randomised, phase 3 study was done across 200 hospitals and cancer centres in 20 countries.
Aim: Lenvatinib plus everolimus is approved for the treatment of advanced renal cell carcinoma (RCC) after one prior vascular endothelial growth factor-targeted therapy. Lenvatinib plus pembrolizumab demonstrated promising antitumor activity in a Phase I/II trial of RCC.
Methods: We describe the rationale and design of the CLEAR study, a three-arm Phase III trial comparing lenvatinib plus everolimus and lenvatinib plus pembrolizumab versus sunitinib monotherapy for first-line treatment of RCC.